Deutsche Bank AG Buys New Position in Medpace Holdings, Inc. $MEDP

Deutsche Bank AG bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, HoldingsChannel reports. The institutional investor bought 4,677 shares of the company’s stock, valued at approximately $2,477,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BOKF NA boosted its position in shares of Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after purchasing an additional 20 shares in the last quarter. Valeo Financial Advisors LLC raised its holdings in shares of Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after purchasing an additional 21 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Medpace by 5.6% in the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after purchasing an additional 24 shares in the last quarter. Schulhoff & Co. Inc. lifted its stake in Medpace by 1.1% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after purchasing an additional 25 shares during the last quarter. Finally, Balefire LLC lifted its stake in Medpace by 6.1% during the first quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after purchasing an additional 26 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MEDP. TD Cowen lifted their price target on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Barclays set a $600.00 price objective on Medpace in a research report on Thursday, July 23rd. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Mizuho lifted their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Finally, Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $584.18.

Insider Transactions at Medpace

In other Medpace news, Director Brian T. Carley sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total value of $3,043,150.00. Following the completion of the sale, the director directly owned 27,825 shares of the company’s stock, valued at $16,935,129.75. The trade was a 15.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the transaction, the director owned 3,798 shares in the company, valued at approximately $2,302,157.70. This trade represents a 65.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 129,963 shares of company stock worth $79,364,624. 20.50% of the stock is owned by corporate insiders.

Medpace Trading Down 1.2%

MEDP opened at $611.57 on Friday. The stock has a market cap of $17.07 billion, a price-to-earnings ratio of 35.85, a PEG ratio of 2.76 and a beta of 1.15. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The stock has a fifty day moving average price of $562.52 and a 200 day moving average price of $493.80.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period in the prior year, the firm posted $3.10 EPS. The business’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.